Olaparib tablets and capsules are also used to treat ovarian cancer in people with a specific gene who have not improved or who have worsened after treatment with at least three other therapies. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Olaparib brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Lynparza (olaparib) tablets cost price in India.
The order for Olaparib will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Lynparza (olaparib) tablets, for oral use. Initial U.S. Approval: 2014
Generic Name: Olaparib
Tablets: 30 mg and 90 mg.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Olaparib on prescription and Import License in Patient's Name only.
For overseas patients, Olaparib can be made available in Send your enquiry to find Olaparib in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For LYNPARZA (olaparib) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Lynparza shows benefits in prostate cancer For More Details
The European Medicines Agency Accepts Regulatory Submission for LYNPARZA® (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer.
Dated: APRIL 3, 2018